Kimal PLC, a leading provider of procedure packs and innovative medical solutions, is proud to announce the signing of an exclusive distribution agreement with CELOX™ PPH Ltd. This partnership will bring the revolutionary CELOX™ PPH Uterine Haemostatic Tamponade, designed to manage postpartum haemorrhage (PPH), to hospitals across the United Kingdom.

PPH is a widespread and critical complication of childbirth, affecting approximately 14 million women each year and leading to nearly one quarter of all maternal deaths. This could be avoided by implementing cost-effective and resource-appropriate interventions, but existing treatment options are limited. CELOX™ PPH was designed to address this by rapidly and effectively managing postnatal blood loss in any setting, without the need for power, suction, saline or specific storage conditions. The tamponade demonstrates 100 % haemostasis for grade 1 and 2 bleeding (up to 2,500 ml) in all deliveries, and 95.6 % haemostasis for up to grade 3 bleeding (8,000 ml) in vaginal deliveries, while also reducing hysterectomy rates by 78 % compared to the current treatment options.

Under this agreement, Kimal PLC will leverage its extensive distribution network and established relationships within the NHS and private healthcare sectors to ensure that the CELOX™ PPH device is available to healthcare providers across the UK. This collaboration aligns with Kimal’s commitment to improving patient outcomes by providing access to innovative medical technology. Matthew Press, CEO of Kimal PLC, commented, ” Earlier this year, the Birth Trauma Report brought to prominence a series of concerns that Kimal has been working with the NHS on for some time. This exciting partnership with CELOX, and specifically their innovative CELOX™ PPH Uterine Haemostatic Tamponade, is another cornerstone element of providing a portfolio of products to the NHS, that improve maternity outcomes, including those highlighted in the Birth Trauma Report published earlier this year”.

Andy Sutcliffe, Marketing and Commercial Director of CELOX™ PPH Ltd (A subsidiary of Medtrade Products Ltd), said “Across the NHS there is a real focus on reducing birth trauma and improving the experience of all new mothers. Reducing the complications associated with Post Partum Haemorrhage, a leading global cause of maternal mortality and morbidity, is a key part of that strategy. We are really excited about this new partnership with Kimal and bringing CELOX™ PPH, a life changing innovation, to clinicians and patients across the UK.”

About Kimal – Founded in 1964, Founded in 1964, Kimal is an innovative manufacturer and distributor of customised procedure packs and vascular access devices to clinical departments in over seventy countries worldwide. The Company manufactures and distributes over two million procedure packs and vascular access devices across its international operations, which sees over 500 people employed across six countries.

About Medtrade – Established in 1999, Medtrade is a UK-based biotechnology company developing and launching industry-leading solutions to partners across the world. With offices in Crewe, UK and New York, US, the experienced leadership, and specialist teams are committed to supporting business partners and healthcare practitioners with market-leading solutions across women’s health, wound care, trauma, and the haemostasis sectors. Integral to the success of Medtrade is the continued focus on innovation that addresses key global healthcare challenges such as biofilms, wound treatment, infection prevention, pressure injury prevention and control of bleeding. CELOX™ PPH Ltd is a subsidiary of Medtrade focused on pioneering solutions for women’s health.

For more information about the CELOX™ PPH device and Kimal PLC’s distribution services, please visit https://www.celoxpph.com, or email us at maternity@kimal.com.